EP1446665A2 - Marqueurs d'affinite 3 a codage isotopique - Google Patents

Marqueurs d'affinite 3 a codage isotopique

Info

Publication number
EP1446665A2
EP1446665A2 EP02774759A EP02774759A EP1446665A2 EP 1446665 A2 EP1446665 A2 EP 1446665A2 EP 02774759 A EP02774759 A EP 02774759A EP 02774759 A EP02774759 A EP 02774759A EP 1446665 A2 EP1446665 A2 EP 1446665A2
Authority
EP
European Patent Office
Prior art keywords
formula
group
derivative
protein
residue
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP02774759A
Other languages
German (de)
English (en)
Inventor
Hans-Georg Lerchen
Hans-Ulrich Siegmund
Dorian Immler
Andreas Schumacher
Daniel Auriel
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bayer AG
Original Assignee
Bayer Healthcare AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE10234415A external-priority patent/DE10234415A1/de
Application filed by Bayer Healthcare AG filed Critical Bayer Healthcare AG
Publication of EP1446665A2 publication Critical patent/EP1446665A2/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/44—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having three double bonds between ring members or between ring members and non-ring members
    • C07D207/444—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having three double bonds between ring members or between ring members and non-ring members having two doubly-bound oxygen atoms directly attached in positions 2 and 5
    • C07D207/448—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having three double bonds between ring members or between ring members and non-ring members having two doubly-bound oxygen atoms directly attached in positions 2 and 5 with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to other ring carbon atoms, e.g. maleimide
    • C07D207/452—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having three double bonds between ring members or between ring members and non-ring members having two doubly-bound oxygen atoms directly attached in positions 2 and 5 with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to other ring carbon atoms, e.g. maleimide with hydrocarbon radicals, substituted by hetero atoms, directly attached to the ring nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/13—Labelling of peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/06026—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atom, i.e. Gly or Ala
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/06034—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms
    • C07K5/06052—Val-amino acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06104—Dipeptides with the first amino acid being acidic
    • C07K5/06113—Asp- or Asn-amino acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06139—Dipeptides with the first amino acid being heterocyclic
    • C07K5/06147—Dipeptides with the first amino acid being heterocyclic and His-amino acid; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06139—Dipeptides with the first amino acid being heterocyclic
    • C07K5/06165—Dipeptides with the first amino acid being heterocyclic and Pro-amino acid; Derivatives thereof
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2458/00—Labels used in chemical analysis of biological material
    • G01N2458/15—Non-radioactive isotope labels, e.g. for detection by mass spectrometry
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T436/00—Chemistry: analytical and immunological testing
    • Y10T436/24—Nuclear magnetic resonance, electron spin resonance or other spin effects or mass spectrometry

Abstract

Nouveaux marqueurs à codage isotopique (ICAT) pour l'analyse par spectrométrie de masse de protéines, ainsi que préparation et utilisation desdits marqueurs.
EP02774759A 2001-11-09 2002-10-30 Marqueurs d'affinite 3 a codage isotopique Withdrawn EP1446665A2 (fr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
DE10154745 2001-11-09
DE10154745 2001-11-09
DE10234415 2002-07-29
DE10234415A DE10234415A1 (de) 2001-11-09 2002-07-29 Isotopencodierte Affinitätsmarker 3
PCT/EP2002/012105 WO2003040288A2 (fr) 2001-11-09 2002-10-30 Marqueurs d'affinite 3 a codage isotopique

Publications (1)

Publication Number Publication Date
EP1446665A2 true EP1446665A2 (fr) 2004-08-18

Family

ID=26010525

Family Applications (1)

Application Number Title Priority Date Filing Date
EP02774759A Withdrawn EP1446665A2 (fr) 2001-11-09 2002-10-30 Marqueurs d'affinite 3 a codage isotopique

Country Status (5)

Country Link
US (1) US7132295B2 (fr)
EP (1) EP1446665A2 (fr)
AU (1) AU2002340490A1 (fr)
CA (1) CA2466328A1 (fr)
WO (1) WO2003040288A2 (fr)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004070352A2 (fr) * 2003-01-30 2004-08-19 Applera Corporation Procedes, melanges, kits et compositions relatives a la determination d'analytes
DE602004009824T2 (de) * 2003-11-26 2008-03-06 Applera Corp., Framingham Analyse von massenspektraldaten in den ruhigen gebieten
US20050148087A1 (en) * 2004-01-05 2005-07-07 Applera Corporation Isobarically labeled analytes and fragment ions derived therefrom
US20050148771A1 (en) 2004-01-05 2005-07-07 Applera Corporation. Active esters of N-substituted piperazine acetic acids, including isotopically enriched versions thereof
JP4832312B2 (ja) * 2004-01-05 2011-12-07 ディーエイチ テクノロジーズ デベロップメント プライベート リミテッド 標識試薬および標識化分析物の混合物を含む、標識試薬、標識化分析物、およびそれらに由来するフラグメントイオン、ならびにそれらの分析方法
US7355045B2 (en) 2004-01-05 2008-04-08 Applera Corporation Isotopically enriched N-substituted piperazine acetic acids and methods for the preparation thereof
US20050147985A1 (en) * 2004-01-05 2005-07-07 Applera Corporation Mixtures of isobarically labeled analytes and fragments ions derived therefrom
US20050269267A1 (en) * 2004-03-19 2005-12-08 Perkinelmer Las, Inc. Separations platform based upon electroosmosis-driven planar chromatography
CN1304845C (zh) * 2004-04-14 2007-03-14 中国科学院上海有机化学研究所 一种新型含碘树脂衍生物用在基于质谱的蛋白组学研究中的方法
US20070048752A1 (en) * 2004-07-12 2007-03-01 Applera Corporation Mass tags for quantitative analyses
WO2006017208A1 (fr) * 2004-07-12 2006-02-16 Applera Corporation Marqueurs de masse pour analyses quantitatives
EP2476756A1 (fr) 2005-06-15 2012-07-18 Massachusetts Institute of Technology Lipides contenant des amines et utilisations associées
WO2007058893A2 (fr) * 2005-11-10 2007-05-24 Perkinelmer Life And Analytical Sciences Systemes de separations par electrochromatographie plane/chromatographie de fine couche
US20070161030A1 (en) * 2005-12-08 2007-07-12 Perkinelmer Las, Inc. Micelle-and microemulsion-assisted planar separations platform for proteomics
US8975404B2 (en) * 2006-01-24 2015-03-10 Dh Technologies Development Pte. Ltd. Labeling reagents for analyte determination and methods and compounds used in making the same
US20070251824A1 (en) * 2006-01-24 2007-11-01 Perkinelmer Las, Inc. Multiplexed analyte quantitation by two-dimensional planar electrochromatography
US7906341B2 (en) * 2006-06-30 2011-03-15 Dh Technologies Development Pte, Ltd. Methods, mixtures, kits and compositions pertaining to analyte determination
US7977102B2 (en) * 2007-06-15 2011-07-12 Los Alamos National Security, Llc Isotopically labeled compositions and method
MX2011004859A (es) 2008-11-07 2011-08-03 Massachusetts Inst Technology Lipidoides de aminoalcohol y usos de los mismos.
PT2506857T (pt) 2009-12-01 2018-05-14 Translate Bio Inc Entrega de arnm para o acréscimo de proteínas e enzimas em doenças genéticas humanas
US9193827B2 (en) 2010-08-26 2015-11-24 Massachusetts Institute Of Technology Poly(beta-amino alcohols), their preparation, and uses thereof
EP2691443B1 (fr) 2011-03-28 2021-02-17 Massachusetts Institute of Technology Lipomères conjugués et utilisations associées
TR201910686T4 (tr) 2011-06-08 2019-08-21 Translate Bio Inc Mrna iletimine yönelik lipit nanopartikül bileşimleri ve yöntemler.
US20150267192A1 (en) 2012-06-08 2015-09-24 Shire Human Genetic Therapies, Inc. Nuclease resistant polynucleotides and uses thereof
WO2014028487A1 (fr) 2012-08-13 2014-02-20 Massachusetts Institute Of Technology Lipidoïdes contenant des amines et leurs utilisations
PL2968586T3 (pl) 2013-03-14 2019-01-31 Translate Bio, Inc. Kompozycje mrna cftr i związne z nimi sposoby i zastosowania
EA201591229A1 (ru) 2013-03-14 2016-01-29 Шир Хьюман Дженетик Терапис, Инк. Способы очистки матричной рнк
US9315472B2 (en) 2013-05-01 2016-04-19 Massachusetts Institute Of Technology 1,3,5-triazinane-2,4,6-trione derivatives and uses thereof
NZ718817A (en) 2013-10-22 2020-07-31 Massachusetts Inst Technology Lipid formulations for delivery of messenger rna
EP4276176A3 (fr) 2013-10-22 2024-01-10 Translate Bio, Inc. Thérapie arnm pour déficience en argininosuccinate synthétase
EP3060258A1 (fr) 2013-10-22 2016-08-31 Shire Human Genetic Therapies, Inc. Thérapie à l'arnm pour la phénylcétonurie
EA201691696A1 (ru) 2014-04-25 2017-03-31 Шир Хьюман Дженетик Терапис, Инк. Способы очистки матричной рнк
AU2015266764B2 (en) 2014-05-30 2019-11-07 Translate Bio, Inc. Biodegradable lipids for delivery of nucleic acids
CN106795142B (zh) 2014-06-24 2022-11-04 川斯勒佰尔公司 用于递送核酸的立体化学富集组合物
WO2016004202A1 (fr) 2014-07-02 2016-01-07 Massachusetts Institute Of Technology Lipidoïdes dérivés de polyamine-acide gras et leurs utilisations
MA47603A (fr) 2017-02-27 2020-01-01 Translate Bio Inc Nouvel arnm cftr à codons optimisés
WO2018213476A1 (fr) 2017-05-16 2018-11-22 Translate Bio, Inc. Traitement de la fibrose kystique par administration d'arnm à codons optimisés codant pour la cftr
CA3108544A1 (fr) 2018-08-24 2020-02-27 Translate Bio, Inc. Procedes de purification d'arn messager

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4190647A (en) * 1979-01-26 1980-02-26 Sloan-Kettering Institute For Cancer Research Polypeptides and methods
DE69912444T3 (de) * 1998-08-25 2010-05-06 University Of Washington, Seattle Schnelle quantitative analyse von proteinen oder proteinfunktionen in komplexen gemischen

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO03040288A3 *

Also Published As

Publication number Publication date
AU2002340490A1 (en) 2003-05-19
WO2003040288A3 (fr) 2003-12-11
CA2466328A1 (fr) 2003-05-15
US20050049406A1 (en) 2005-03-03
US7132295B2 (en) 2006-11-07
WO2003040288A2 (fr) 2003-05-15

Similar Documents

Publication Publication Date Title
EP1446665A2 (fr) Marqueurs d'affinite 3 a codage isotopique
DE69738353T2 (de) Radiometall-bindende peptide analoge
EP0355572B1 (fr) Dérivés de peptides, leur production et utilisation
DE602004006254T2 (de) Auf festen oberflächen gebundene metallchelatkomplexe zur herstellung von peptiden
EP2046813B1 (fr) Dérivés de méthotrexate de liaison protéique et médicaments contenant lesdits dérivés
DE2659758A1 (de) Carba-derivate von somatostatin, verfahren zu ihrer herstellung und arzneimittel
DE4119544C1 (fr)
EP0292729A2 (fr) Procédé de synthèse de peptides en phase solide
US20090130769A1 (en) Novel Cross-Linkers For Obtaining Structure Information On Molecule Complexes
EP1448996A2 (fr) Marqueurs d'affinite 2 a codage isotopique
DE10319611A1 (de) Isotopencodierte Affinitätsmarker 4
EP1448994A2 (fr) Marqueurs d'affinite codes par des isotopes
DE10234415A1 (de) Isotopencodierte Affinitätsmarker 3
DE2202613B2 (de) Verfahren zur Herstellung von Peptiden
DE4004296A1 (de) Verbesserte markierte haptene, verfahren zu deren herstellung sowie verwendung dieser markierten haptene in immunoassays
EP0475184A1 (fr) Procédé de production de peptides par synthèse à phase solide
DE10234416A1 (de) Isotopencodierte Affinitätsmarker 2
EP0024664B1 (fr) Amides de peptides et procédé pour leur préparation
EP2051992A1 (fr) Procédé de fabrication de produits de condensation de dérivés de glycine n-substituée (peptoïdes) par des réactions séquentielles de ugi à plusieurs composants
DE4431317A1 (de) Schutz- bzw. Ankergruppen und deren Verwendung
EP1212351A1 (fr) Procede de production de peptidomimetiques cycliques
Olsen et al. Synthesis of a model analog of the cyclic decadepsipeptide intercalating agent luzopeptin A (antibiotic BBM 928A) containing proline, valine, and unsubstituted quinoline substituents
Chiu et al. Cupric Ion Chelation Assisted Synthesis of N (α)-Protected N (ω)-Acridin-9-yl α, ω-Diamino Carboxylic Acids
AT388918B (de) Aminosaeure-oobt-ester
DE10322077A1 (de) Isotopencodierte Affinitätsmarker 6

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20040611

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LI LU MC NL PT SE SK TR

AX Request for extension of the european patent

Extension state: AL LT LV MK RO SI

RIN1 Information on inventor provided before grant (corrected)

Inventor name: AURIEL, DANIEL

Inventor name: SCHUMACHER, ANDREAS

Inventor name: IMMLER, DORIAN

Inventor name: SIEGMUND, HANS-ULRICH

Inventor name: LERCHEN, HANS-GEORG

RBV Designated contracting states (corrected)

Designated state(s): DE ES FR GB IT

17Q First examination report despatched

Effective date: 20050314

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN WITHDRAWN

18W Application withdrawn

Effective date: 20060413